[go: up one dir, main page]

AU6930200A - Use of lentiviral vectors for antigen presentation in dendritic cells - Google Patents

Use of lentiviral vectors for antigen presentation in dendritic cells

Info

Publication number
AU6930200A
AU6930200A AU69302/00A AU6930200A AU6930200A AU 6930200 A AU6930200 A AU 6930200A AU 69302/00 A AU69302/00 A AU 69302/00A AU 6930200 A AU6930200 A AU 6930200A AU 6930200 A AU6930200 A AU 6930200A
Authority
AU
Australia
Prior art keywords
dendritic cells
antigen presentation
lentiviral vectors
lentiviral
vectors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU69302/00A
Inventor
June Kan-Mitchell
Xinqiang Li
Flossie Wong-Staal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
University of California Berkeley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, University of California Berkeley filed Critical University of California
Publication of AU6930200A publication Critical patent/AU6930200A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU69302/00A 1999-08-27 2000-08-23 Use of lentiviral vectors for antigen presentation in dendritic cells Abandoned AU6930200A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38471999A 1999-08-27 1999-08-27
US09384719 1999-08-27
PCT/US2000/023162 WO2001016342A1 (en) 1999-08-27 2000-08-23 Use of lentiviral vectors for antigen presentation in dendritic cells

Publications (1)

Publication Number Publication Date
AU6930200A true AU6930200A (en) 2001-03-26

Family

ID=23518472

Family Applications (1)

Application Number Title Priority Date Filing Date
AU69302/00A Abandoned AU6930200A (en) 1999-08-27 2000-08-23 Use of lentiviral vectors for antigen presentation in dendritic cells

Country Status (4)

Country Link
EP (1) EP1214437A1 (en)
AU (1) AU6930200A (en)
CA (1) CA2392010A1 (en)
WO (1) WO2001016342A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000039304A2 (en) 1998-12-31 2000-07-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
EP1141313A2 (en) 1998-12-31 2001-10-10 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
US7211659B2 (en) 2001-07-05 2007-05-01 Chiron Corporation Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
WO2004044147A2 (en) * 2002-11-07 2004-05-27 Lung-Ji Chang Modified dendritic cells
EP1885186B1 (en) * 2005-06-01 2015-09-02 California Institute Of Technology Method of targeted gene delivery using viral vectors
EP2048955B1 (en) 2006-07-21 2013-08-21 California Institute of Technology Targeted gene delivery for dendritic cell vaccination
SI2770061T1 (en) 2009-07-24 2019-02-28 Immune Design Corp. Non-integrating lentiviral vectors
US9713635B2 (en) 2012-03-30 2017-07-25 Immune Design Corp. Materials and methods for producing improved lentiviral vector particles
AU2013237900B2 (en) 2012-03-30 2017-07-27 Immune Design Corp. Lentiviral vector particles having improved transduction efficiency for cells expressing DC- SIGN
US8323662B1 (en) 2012-03-30 2012-12-04 Immune Design Corp. Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein
US9493789B2 (en) * 2014-04-24 2016-11-15 Miltenyi Biotec Gmbh Automated generation of genetically modified stem cells
CN114836567A (en) 2016-06-16 2022-08-02 纽希得营养澳大利亚私人有限公司 Event rape NS-B50027-4 of excellent variety
GB202105278D0 (en) * 2021-04-13 2021-05-26 Imperial College Innovations Ltd Cell therapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2286819A1 (en) * 1997-04-17 1998-10-22 Flossie Wong-Staal Use of lentiviral vectors for antigen presentation in dendritic cells

Also Published As

Publication number Publication date
WO2001016342A1 (en) 2001-03-08
CA2392010A1 (en) 2001-03-08
EP1214437A1 (en) 2002-06-19
WO2001016342A9 (en) 2002-09-19

Similar Documents

Publication Publication Date Title
AU7158398A (en) Use of lentiviral vectors for antigen presentation in dendritic cells
AU5731400A (en) Methods of preparing electrochemical cells
AU1796601A (en) Methods of preparing electrochemical cells
AU2001259624A1 (en) Modulation of antigen processing using phagocytic cells
AU2002322211A1 (en) Methods and compisitions for activation human t cells in vitro
AU6930200A (en) Use of lentiviral vectors for antigen presentation in dendritic cells
AU6140998A (en) Peptides and peptide-loaded antigen presenting cells for the activation of ctl
AU2001260847A1 (en) Compositions isolated from skin cells and methods for their use
AU2001233132A1 (en) Hybrid adeno-retroviral vector for the transfection of cells
AU4191600A (en) An eeprom cell on soi
AU2403901A (en) Maturation-promoting agent for immature dendritic cells
AU4642600A (en) Methods and compositions for use in potentiating antigen presentation by antigenpresenting cells
AU2926000A (en) Packaging cells for retroviral vectors
AU1919201A (en) Mammalian receptor proteins; related reagents and methods
AU1152397A (en) Methods for in vivo t cell activation by antigen-pulsed dendritic cells
AU1796501A (en) Methods of preparing electrochemical cells
AU2977500A (en) Advanced antigen presentation platform
AU3916400A (en) Human transmembrane proteins
AU1618500A (en) Human cell surface receptor proteins
AU7308200A (en) Novel hev antigenic peptide and methods
AU2001286205A1 (en) Novel dendritic cell wall membrane and use thereof
AU2002213982A1 (en) Device for determining skin aging in vitro
AU3215800A (en) Identification of broadly reactive hla restricted t cell epitopes
AU2001289603A1 (en) Methods and means for the complementation of viral protein expression in stable cell lines
AU2001274815A1 (en) Compositions and methods for inducing activation of dendritic cells

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase